A Phase 1/2 interventional study of Bletilla formosana (BF) powder and Placebo in Prediabetes, sponsored by Chang Gung Memorial Hospital. Not yet recruiting at 3 sites in Taiwan. Open to participants aged 30 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-07-15.
Sponsored by Chang Gung Memorial Hospital · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies in Prediabetic State with a site in Taiwan — 4 open to participants now, 6 under way, 1 of them phase 3. Prediabetic State · Taiwan.
Among the 15 studies in Prediabetic State with a site in Taiwan, this one is the 9th largest by planned enrollment of the 12 interventional ones that give a count, is one of 3 that started in 2026, is the only one in phase 1/2, and was the 14th registered.
919 studies on the registry are indexed under Prediabetic State; 231 are open to participants now.
Browse Prediabetic State studies →4 of the 15 studies in Prediabetic State with a site in Taiwan are open now. Recruiting first, the newest first:
Eli Lilly and Company · Sites in Taiwan, United States, Argentina and 9 more countries
Ages 18+
National Yang Ming Chiao Tung University · Sites in Taiwan
Ages 20–60 · Healthy volunteers
Chung Shan Medical University · Sites in Taiwan
Ages 18–70 · Healthy volunteers
A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →
Of the 144 Prediabetic State studies recruiting now, 51 (35%) set no upper age limit and 83 (58%) stop at 75 or younger; 12 take children under 18; 54 take healthy volunteers.
This study: 30 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 3 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 94 is above the median of 62 across 763 interventional studies indexed under Prediabetic State.
Median enrollment 151 across the 12 interventional studies, 1,530 across the 2 observational. Of the 5 that completed or were terminated, 2 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 15 have an industry lead sponsor. The 10 most frequent:
Chang Gung Memorial Hospital is the lead sponsor of 1,098 studies on the registry; 241 are open to participants now.
Chang Gung Memorial Hospital has 2 studies filed under Prediabetic State — fewer than ten, so there is no comparison to draw.
2 of the studies in Prediabetic State with a site in Taiwan that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07609290Chimei Medical CenterEffects of Exercise Snacks on Clinical and Health Outcomes | 2026-12-31 |
| NCT07704944Chang Gung Memorial HospitalSafety and Dose-Response of Bletilla Formosana in Prediabetic Subjects | 2027-07-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 15 studies in Prediabetic State with a site in Taiwan, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study evaluates the safety and preliminary efficacy of Bletilla formosana (BF), a traditional herbal medicine, in adults with prediabetes. Prediabetes is a high-risk condition where blood sugar levels are elevated, often leading to type 2 diabetes. While lifestyle changes are the standard treatment, researchers are exploring herbal supplements as a complementary way to support metabolic health. Preclinical research has shown that BF possesses anti-inflammatory properties and may help regulate blood glucose. Participants in this study will be randomly assigned to receive either a high dose of BF, a low dose of BF, or a placebo (an inactive substance) for 12 weeks. The total study duration is approximately 24 weeks, involving four clinic visits for blood tests and safety monitoring to see how BF affects blood sugar markers and inflammation.
This is a single-center, Phase I/II, randomized, double-blind, placebo-controlled, parallel-design trial. The primary goal is to translate robust preclinical findings-where BF extract was shown to inhibit neutrophil-driven inflammation and improve glycemic parameters in animal models-into clinical evidence.
A total of 94 prediabetic subjects (defined by FPG 100-125 mg/dL or HbA1c 5.7%-6.4%) will be enrolled.
Participants will be randomized in a 2:2:1 ratio into one of the following three arms:
High-dose group: 3g Bletilla formosana powder daily. Low-dose group: 1.5g Bletilla formosana powder plus 1.5g placebo daily. Placebo group: 3g inactive placebo powder daily.
The study consists of three distinct phases:
Screening Phase: Up to 2 weeks for eligibility confirmation. Treatment Phase: 12 weeks of oral administration. Follow-up Phase: 12 weeks post-treatment to evaluate sustained efficacy and safety outcomes.
Phase I objectives focus on safety and tolerability, with adverse events (AEs) and serious adverse events (SAEs) graded according to CTCAE v5.0.
Phase II objectives explore preliminary efficacy through changes in fasting plasma glucose (FPG), HbA1c, and HOMA-IR.
Secondary endpoints include assessment of inflammatory biomarkers (TNF-α, IL-6, and CRP) and lipid profiles.
Clinical assessments, including 12-lead ECG and comprehensive laboratory testing, are scheduled at Screening, Week 6, Week 12 (end of treatment), and Week 24 (end of study).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive 3g of Bletilla formosana powder daily for 12 weeks. To maintain blinding, the total dose is divided into two 1.5g sachets (one in the morning and one in the evening).
Drug: Bletilla formosana (BF) powder
Participants receive 1.5g of Bletilla formosana powder and 1.5g of placebo powder daily for 12 weeks. To maintain blinding, this is administered as one active sachet and one matching placebo sachet (one in the morning and one in the evening).
Drug: Bletilla formosana (BF) powder · Other: Placebo
Participants receive 3g of inactive placebo powder daily for 12 weeks. To maintain blinding, this is administered as two matching placebo sachets (one in the morning and one in the evening).
Other: Placebo
A traditional Chinese medicinal herb (Taiwanese ground orchid). The raw material is derived from the approved botanical species and medicinal part listed in the Taiwan Herbal Pharmacopoeia.
An inactive powder matching the appearance and dosage form of the BF powder, consisting of starch and caramel coloring.
Number of Participants with at Least One Treatment-Emergent Adverse Event (AE)
Incidence of all adverse events (AEs) graded by CTCAE v5.0.
Time frame: From baseline to Week 24.
Number of Participants with Serious Adverse Events (SAEs)
Number of participants experiencing life-threatening or fatal events according to ICH-GCP definitions.
Time frame: From baseline to Week 24
Change from Baseline in Fasting Plasma Glucose (FPG) (mg/dL)
Change in fasting blood sugar levels to assess the preliminary glycemic efficacy of Bletilla formosana.
Time frame: Baseline, Week 6, Week 12, and Week 24.
Change from Baseline in Glycated Hemoglobin (HbA1c) (%)
Assessment of average blood glucose control over time.
Time frame: Baseline, Week 6, Week 12, and Week 24.
Change from Baseline in Homeostatic Model Assessment for Insulin Resistance (HOMA-IR)
Calculated using fasting insulin and glucose levels to assess changes in insulin sensitivity.
Time frame: Baseline, Week 6, Week 12, and Week 24.
Change from Baseline in Tumor Necrosis Factor-alpha (TNF-α) (pg/mL)
To evaluate the anti-inflammatory effects of Bletilla formosana.
Time frame: Baseline, Week 6, Week 12, and Week 24.
Change from Baseline in Interleukin-6 (IL-6) (pg/mL)
To evaluate the anti-inflammatory effects of Bletilla formosana.
Time frame: Baseline, Week 6, Week 12, and Week 24.
Change from Baseline in C-reactive protein (CRP) (mg/dL)
To evaluate the anti-inflammatory effects of Bletilla formosana.
Time frame: Baseline, Week 6, Week 12, and Week 24.
Change from Baseline in Total Cholesterol (mg/dL)
Assessment of lipid profiles using standard laboratory methods
Time frame: Baseline, Week 6, Week 12, and Week 24.
Change from Baseline in High-Density Lipoprotein (HDL) (mg/dL)
Assessment of lipid profiles using standard laboratory methods.
Time frame: Baseline, Week 6, Week 12, and Week 24.
Change from Baseline in Low-Density Lipoprotein (LDL) (mg/dL)
Assessment of lipid profiles using standard laboratory methods.
Time frame: Baseline, Week 6, Week 12, and Week 24.
Change from Baseline in Triglycerides (TG) (mg/dL)
Assessment of lipid profiles using standard laboratory methods.
Time frame: Baseline, Week 6, Week 12, and Week 24.
Change from Baseline in Alanine Aminotransferase (ALT) (U/L)
Assessment of clinical laboratory safety tests to monitor hepatic, renal, and hematologic function.
Time frame: Baseline, Week 6, Week 12, and Week 24.
Change from Baseline in Aspartate Aminotransferase (AST) (U/L)
Assessment of clinical laboratory safety tests to monitor hepatic, renal, and hematologic function.
Time frame: Baseline, Week 6, Week 12, and Week 24.
Change from Baseline in Total Bilirubin (mg/dL)
Assessment of clinical laboratory safety tests to monitor hepatic, renal, and hematologic function.
Time frame: Baseline, Week 6, Week 12, and Week 24.
Change from Baseline in Blood Urea Nitrogen (BUN) (mg/dL)
Assessment of clinical laboratory safety tests to monitor hepatic, renal, and hematologic function.
Time frame: Baseline, Week 6, Week 12, and Week 24.
Change from Baseline in Serum Creatinine (mg/dL)
Assessment of clinical laboratory safety tests to monitor hepatic, renal, and hematologic function.
Time frame: Baseline, Week 6, Week 12, and Week 24.
Change from Baseline in White Blood Cell Count (WBC) (10^3/μL)
Assessment of clinical laboratory safety tests to monitor hepatic, renal, and hematologic function.
Time frame: Baseline, Week 6, Week 12, and Week 24.
Change from Baseline in Hemoglobin (Hb) (g/dL)
Assessment of clinical laboratory safety tests to monitor hepatic, renal, and hematologic function.
Time frame: Baseline, Week 6, Week 12, and Week 24.
Change from Baseline in Platelet Count (10^3/μL)
Assessment of clinical laboratory safety tests to monitor hepatic, renal, and hematologic function.
Time frame: Baseline, Week 6, Week 12, and Week 24.
Plan to share: No — The study team does not have a plan to share individual participant data at this time to maintain participant confidentiality as stated in the informed consent.
No publications or documents are linked to this record.
Start is estimated for Jul 2026; primary completion for Jul 2027, 12 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Chang Gung Memorial Hospital →